China News Service, April 27 (Reporter Chen Jing) At present, China's cancer patients still have a large number of unmet needs in terms of drug accessibility, payment accessibility, service accessibility, and medication compliance.
The reporter learned on the 27th that pharmaceutical companies have joined hands with a comprehensive service platform for medical treatment, medication and payment to jointly promote the availability of Phuket Hua and Tai Ji Hua after their listing in China.
Pugeta is a selective RET inhibitor approved in China for the treatment of related non-small cell lung cancer.
Taijihua (Avatinib tablets) is a drug approved in China for the treatment of related gastrointestinal stromal tumors (GIST).
Zhao Ping, general manager of the Greater China region of related pharmaceutical companies, told reporters that the two parties will promote the linkage of pharmaceutical companies, medical institutions, and patients to form an intelligent medical service system that radiates across the country, and create a complete online medical treatment, online and offline doctor-patient education, and patient education. The whole-process service chain of disease course management helps patients solve medical payment problems, so that more patients can enjoy high-quality medical services.
Thyroid cancer is the most common endocrine malignant tumor, and its incidence has increased significantly in recent years.
The reporter learned on the 27th that the selective RET (metastatic transfection rearrangement gene) inhibitor Pugeta has been accepted by the National Medical Products Administration (NMPA) for its indications for thyroid cancer and has been included in the priority review.
According to reports, this is half a year earlier than the original plan.
RET fusion and activating mutations are key disease drivers for many cancer types.
It is understood that currently, there are no precise targeted drugs for RET-mutated thyroid cancer in China. Patients can only receive treatment with multi-target non-selective drugs, with limited efficacy and poor safety.
This time, the State Food and Drug Administration accepted the indications for the expansion of Phughwa is based on a global phase I/II ARROW clinical study.
Expanded indications include advanced or RET gene mutation medullary thyroid carcinoma (MTC) that requires systemic treatment, and related advanced or metastatic RET fusion-positive thyroid cancer.
Dr. Yang Jianxin, chief medical officer of related pharmaceutical companies, said that the indication of Phuket Huaxin can be approved as soon as possible, which will bring hope to more Chinese patients.
Previously, in March of this year, NMPA passed the priority review and approved the conditional approval of Puhui Hua as a national first-class innovative drug listing application for locally advanced or metastatic non-small cell lung cancer that has previously received platinum-containing chemotherapy with RET gene fusion positive. Treatment of adult patients.
(Finish)